Workflow from Scientific Research

CONSORT diagram showing patients enrolled and treated at different DLs. * Without lymphodepletion; a ITT patient populationpatients who signed informed consent and underwent leukapheresis with the intent to receive gavo-cel as part of the phase 1 portion of the study; ^ Split dose of 1 x 10 8 and 2 x 10 8 cells on days 0 and 3. MSLN, mesothelin.

DOI